CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $9.00.

CTMX has been the topic of a number of research analyst reports. Piper Sandler increased their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Barclays boosted their target price on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. Guggenheim reissued a “buy” rating and set a $10.00 price target on shares of CytomX Therapeutics in a report on Monday. Cantor Fitzgerald raised their price target on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Finally, HC Wainwright lifted their price objective on CytomX Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th.

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CTMX. Seven Fleet Capital Management LP bought a new position in shares of CytomX Therapeutics in the 4th quarter worth approximately $208,000. Empowered Funds LLC bought a new stake in CytomX Therapeutics during the fourth quarter valued at approximately $133,000. XTX Topco Ltd increased its holdings in CytomX Therapeutics by 63.9% during the fourth quarter. XTX Topco Ltd now owns 47,991 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 18,705 shares during the last quarter. Virtus Investment Advisers LLC bought a new position in CytomX Therapeutics in the fourth quarter worth approximately $270,000. Finally, Twinbeech Capital LP bought a new position in CytomX Therapeutics in the fourth quarter worth approximately $75,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Stock Down 3.0%

Shares of NASDAQ CTMX opened at $4.88 on Wednesday. The firm’s 50-day moving average price is $5.15 and its 200-day moving average price is $3.98. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $6.35. The company has a market cap of $826.82 million, a PE ratio of 12.20 and a beta of 2.44.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.